Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
-
Clin. Gastroenterol. Hepatol. · Jul 2006
A prospective study of complications of endoscopic retrograde cholangiopancreatography and endoscopic ultrasound in an ambulatory endoscopy center.
Our aim was to assess the safety of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS) in an ambulatory endoscopy center (AEC). ⋯ ERCP and EUS can be performed in an AEC, provided mechanisms for admission and anesthesia support are in place. The assessment of comprehensive complications is more reflective of adverse events related to ERCP and EUS than consensus criteria alone.
-
Clin. Gastroenterol. Hepatol. · May 2006
Comparative StudySafety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies.
Studies show that tegaserod effectively relieves the symptoms of chronic constipation/idiopathic constipation (CC). This pooled analysis assessed the safety and tolerability of tegaserod in a large dataset of CC patients. ⋯ Tegaserod is well tolerated by patients with CC during 12 weeks of treatment.
-
Clin. Gastroenterol. Hepatol. · May 2006
Comparative StudyThe infant gastroesophageal reflux questionnaire revised: development and validation as an evaluative instrument.
Gastroesophageal reflux disease (GERD) is frequently experienced by infants, and disease-specific measures are needed to evaluate treatment benefits. We revised the Infant Gastroesophageal Reflux Questionnaire (I-GERQ) on the basis of information from parents of infants with GERD and physicians and subjected it to a psychometric evaluation. ⋯ This study demonstrated the I-GERQ-R is a reliable, valid, and clinically responsive measure of infant GERD symptoms.
-
Clin. Gastroenterol. Hepatol. · May 2006
Comparative StudySerious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
Long-term safety data for infliximab and other therapies in Crohn's disease (CD) are needed. ⋯ Mortality rates were similar between infliximab- and non-infliximab-treated patients. The increased risk for serious infection observed with infliximab likely was owing to disease severity and prednisone use.